SCHEMBL25801774

SCHEMBL25801774

CCOP(C)(=O)C(Cc1nc(Cc2ccc(C(C)(C)C)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 4/20 0.34
ZAP70 P43403 6/20 0.34
SRC P12931 2/20 0.34
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
NPC1 O15118 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
TP53 P04637 2/20 0.33
CYP2C9 P11712 1/20 0.33
EGLN1 Q9GZT9 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
RAB9A P51151 1/20 0.32
MAPT P10636 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25801885 0.93 MEN1 (0.42) KMT2AMEN1LMNAZAP70SRC
SCHEMBL25804590 0.92 KMT2A (0.35) KMT2AMEN1LMNAZAP70SRC
SCHEMBL25801972 0.91 MEN1 (0.35) KMT2AMEN1LMNAZAP70SRC
SCHEMBL25801748 0.91 MAPT (0.41) KMT2AMEN1LMNAZAP70SRC
SCHEMBL25801969 0.91 MEN1 (0.35) KMT2AMEN1LMNAZAP70SRC
SCHEMBL25801790 0.89 MEN1 (0.34) KMT2AMEN1LMNAZAP70SRC
SCHEMBL25801813 0.88 SRC (0.33) KMT2AMEN1LMNASRC
SCHEMBL25801784 0.88 MAPT (0.39) KMT2AMEN1LMNAZAP70SRC
SCHEMBL25802061 0.88 MEN1 (0.36) KMT2AMEN1LMNAZAP70SRC
SCHEMBL25801911 0.88 MAPT (0.37) KMT2AMEN1LMNACYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 KMT2A 3125/4885MEN1 4504/4885LMNA 3388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.